KRX Bio Technology Transfer Index

SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.

Q1 2026 earnings release on 2026-05-18 with high price impact expected based on results versus expectations scheduled.

Corporate briefing (IR) for domestic and international institutional investors to explain company status scheduled; 1% price impact as IR sessions typically have limited immediate market reaction analysts estimated.

CEO Dong Ki Lee is scheduled to present research on the company's RNAi platform for ophthalmic diseases at the TIDES USA 2026 conference on May 14, 2026; a 5% price impact is estimated due to potential clinical data updates, scheduled.

Announced on May 13, 2026, that its blockbuster drug 'K-CAB' became the top-prescribed drug in Korea for April 2026, with monthly outpatient prescription sales of KRW 20.8 billion.

Daewoong Pharmaceutical announced its Q1 2026 earnings on May 12, 2026. On a separate basis, revenue was KRW 335.7 billion (+6.2% YoY) while operating profit was KRW 27.4 billion (-34.7% YoY).

On May 12, 2026, the company announced a license-in and co-development agreement with Innovo Therapeutics for the IBD drug candidate 'INV-008'. The total deal size is up to KRW 662.5 billion, including an upfront payment of KRW 6.5 billion.

Scheduled to present clinical data for its 'Grabody-T' platform, including results for Ragistomic (ABL503) and Givastomic (ABL111), at the PEGS Boston conference from May 11-15, 2026 scheduled.

On 2026-05-08, Kolon TissueGene is scheduled to announce the completion of the first US Phase 3 clinical trial for 'TG-C' (formerly Invossa), with top-line data release in July 2026. High impact from the clinical milestone is expected.

Alteogen Q1 2026 earnings announcement: revenue of KRW 71.6 billion and operating profit of KRW 39.3 billion. Results driven by upfront payments from GSK and Biogen. High impact expected due to significant profit growth expected.

Announced Q1 2026 earnings on May 8, 2026, with revenue of KRW 13.1 billion, primarily from technology transfer fees. The company reported holding approximately KRW 190 billion in cash and cash equivalents.

SK Biopharmaceuticals announced record Q1 2026 results on May 7, 2026, with revenue of KRW 227.9 billion (+57.8% YoY) and an operating profit of KRW 89.8 billion (+249.7% YoY), significantly exceeding market expectations, expected. High impact estimated due to the significant earnings surprise.